Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1975 3
1984 1
1985 2
1986 3
1988 2
1989 3
1990 7
1991 5
1992 2
1994 4
1995 6
1996 4
1997 6
1998 6
1999 8
2000 6
2001 2
2002 3
2003 7
2004 7
2005 6
2006 8
2007 6
2008 4
2009 2
2010 7
2011 10
2012 11
2013 8
2014 10
2015 7
2016 15
2017 10
2018 10
2019 11
2020 12
Text availability
Article attribute
Article type
Publication date

Search Results

215 results
Results by year
Filters applied: . Clear all
Page 1
Primary sclerosing cholangitis.
Dyson JK, Beuers U, Jones DEJ, Lohse AW, Hudson M. Dyson JK, et al. Lancet. 2018 Jun 23;391(10139):2547-2559. doi: 10.1016/S0140-6736(18)30300-3. Epub 2018 Feb 13. Lancet. 2018. PMID: 29452711 Review.
Primary sclerosing cholangitis is a rare, chronic cholestatic liver disease characterised by intrahepatic or extrahepatic stricturing, or both, with bile duct fibrosis. ...Primary sclerosing cholangitis is associated with increased malign
Primary sclerosing cholangitis is a rare, chronic cholestatic liver disease characterised by intrahepatic or extrahepat
IgG4-Related Sclerosing Cholangitis and Primary Sclerosing Cholangitis.
Tanaka A. Tanaka A. Gut Liver. 2019 May 15;13(3):300-307. doi: 10.5009/gnl18085. Gut Liver. 2019. PMID: 30205418 Free PMC article. Review.
Sclerosing cholangitis (SC) is defined as a condition with progressive stenosis and destruction of the bile ducts due to diffuse inflammation and fibrosis and currently includes three categories: primary sclerosing cholangitis (PSC), secondary
Sclerosing cholangitis (SC) is defined as a condition with progressive stenosis and destruction of the bile ducts due to diffu
Primary Sclerosing Cholangitis: A Concise Review of Diagnosis and Management.
Fricker ZP, Lichtenstein DR. Fricker ZP, et al. Dig Dis Sci. 2019 Mar;64(3):632-642. doi: 10.1007/s10620-019-05484-y. Epub 2019 Feb 6. Dig Dis Sci. 2019. PMID: 30725292 Review.
Primary sclerosing cholangitis is a rare, chronic cholestatic liver disease characterized by progressive idiopathic stricturing of the biliary system, typically leading to cirrhosis, end-stage liver disease, and colonic or hepatobiliary malignancy. ...When sy
Primary sclerosing cholangitis is a rare, chronic cholestatic liver disease characterized by progressive idiopathic str
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.
Trauner M, Gulamhusein A, Hameed B, Caldwell S, Shiffman ML, Landis C, Eksteen B, Agarwal K, Muir A, Rushbrook S, Lu X, Xu J, Chuang JC, Billin AN, Li G, Chung C, Subramanian GM, Myers RP, Bowlus CL, Kowdley KV. Trauner M, et al. Hepatology. 2019 Sep;70(3):788-801. doi: 10.1002/hep.30509. Epub 2019 Mar 10. Hepatology. 2019. PMID: 30661255 Free PMC article. Clinical Trial.
Primary sclerosing cholangitis (PSC) represents a major unmet medical need. In a phase II double-blind, placebo-controlled study, we tested the safety and efficacy of cilofexor (formerly GS-9674), a nonsteroidal farnesoid X receptor agonist in patients withou
Primary sclerosing cholangitis (PSC) represents a major unmet medical need. In a phase II double-blind, placebo-control
Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.
Lemoinne S, Pares A, Reig A, Ben Belkacem K, Kemgang Fankem AD, Gaouar F, Poupon R, Housset C, Corpechot C, Chazouillères O. Lemoinne S, et al. Clin Res Hepatol Gastroenterol. 2018 Dec;42(6):521-528. doi: 10.1016/j.clinre.2018.06.009. Epub 2018 Aug 9. Clin Res Hepatol Gastroenterol. 2018. PMID: 30100231 Free article.
BACKGROUND & AIMS: In patients with primary sclerosing cholangitis (PSC), ursodeoxycholic acid (UDCA) treatment improves serum liver tests and surrogate markers of prognosis but has no proven effect on survival. ...Fibrates, PPAR agonists with anti-choles …
BACKGROUND & AIMS: In patients with primary sclerosing cholangitis (PSC), ursodeoxycholic acid (UDCA) treatment imp …
norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P, Hirschfield GM, Denk G, Marschall HU, Altorjay I, Färkkilä M, Schramm C, Spengler U, Chapman R, Bergquist A, Schrumpf E, Nevens F, Trivedi P, Reiter FP, Tornai I, Halilbasic E, Greinwald R, Pröls M, Manns MP, Trauner M; European PSC norUDCA Study Group. Fickert P, et al. J Hepatol. 2017 Sep;67(3):549-558. doi: 10.1016/j.jhep.2017.05.009. Epub 2017 May 18. J Hepatol. 2017. PMID: 28529147 Free article. Clinical Trial.
BACKGROUND & AIM: Primary sclerosing cholangitis (PSC) represents a devastating bile duct disease, currently lacking effective medical therapy. 24-norursodeoxycholic acid (norUDCA) is a side chain-shortened C(23) homologue of UDCA and has shown potent ant …
BACKGROUND & AIM: Primary sclerosing cholangitis (PSC) represents a devastating bile duct disease, currently lackin …
Characteristics and Outcomes Reported by Patients With Primary Sclerosing Cholangitis Through an Online Registry.
Kuo A, Gomel R, Safer R, Lindor KD, Everson GT, Bowlus CL. Kuo A, et al. Clin Gastroenterol Hepatol. 2019 Jun;17(7):1372-1378. doi: 10.1016/j.cgh.2018.04.047. Epub 2018 Apr 26. Clin Gastroenterol Hepatol. 2019. PMID: 29705262
BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is a fibrostenosing disease of the bile ducts associated with inflammatory bowel disease (IBD), for which the only treatment is liver transplantation. ...More than half of the participants reported h …
BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is a fibrostenosing disease of the bile ducts associated wi …
Pathogenesis and Management of Pruritus in PBC and PSC.
Kremer AE, Namer B, Bolier R, Fischer MJ, Oude Elferink RP, Beuers U. Kremer AE, et al. Dig Dis. 2015;33 Suppl 2:164-75. doi: 10.1159/000440829. Epub 2015 Dec 7. Dig Dis. 2015. PMID: 26641452 Review.
Pruritus is a preeminent symptom in patients with chronic cholestatic liver disorders such as primary biliary cirrhosis and primary sclerosing cholangitis. ...Treatment options for pruritus of cholestasis remain limited to a few evidence-
Pruritus is a preeminent symptom in patients with chronic cholestatic liver disorders such as primary biliary cirrhosis and
Primary sclerosing cholangitis: diagnostic and therapeutic problems.
Gotthardt D, Chahoud F, Sauer P. Gotthardt D, et al. Dig Dis. 2011;29 Suppl 1:41-5. doi: 10.1159/000331074. Epub 2011 Nov 15. Dig Dis. 2011. PMID: 22104752 Review.
Progressive destruction of bile ducts in primary sclerosing cholangitis (PSC) may lead to end-stage liver disease, portal hypertension and liver failure. ...Patients may present with jaundice, pruritus or ascending cholangitis. Therefore, in pat …
Progressive destruction of bile ducts in primary sclerosing cholangitis (PSC) may lead to end-stage liver disease, port …
Advances in primary sclerosing cholangitis.
Horsley-Silva JL, Carey EJ, Lindor KD. Horsley-Silva JL, et al. Lancet Gastroenterol Hepatol. 2016 Sep;1(1):68-77. doi: 10.1016/S2468-1253(16)30010-3. Epub 2016 Aug 10. Lancet Gastroenterol Hepatol. 2016. PMID: 28404115 Review.
Primary sclerosing cholangitis is a chronic, progressive cholangiopathy that frequently affects men and is associated with inflammatory bowel disease. ...Symptoms of primary sclerosing cholangitis include fatigue, jaundice, pruritus
Primary sclerosing cholangitis is a chronic, progressive cholangiopathy that frequently affects men and is associated w
215 results
Jump to page
Feedback